[go: up one dir, main page]

EE03528B1 - Valatsükloviirvesinikkloriid, selle valmistamismeetod ja kasutamine - Google Patents

Valatsükloviirvesinikkloriid, selle valmistamismeetod ja kasutamine

Info

Publication number
EE03528B1
EE03528B1 EE9700175A EE9700175A EE03528B1 EE 03528 B1 EE03528 B1 EE 03528B1 EE 9700175 A EE9700175 A EE 9700175A EE 9700175 A EE9700175 A EE 9700175A EE 03528 B1 EE03528 B1 EE 03528B1
Authority
EE
Estonia
Prior art keywords
preparation
valaciclovir hydrochloride
valaciclovir
hydrochloride
Prior art date
Application number
EE9700175A
Other languages
English (en)
Other versions
EE9700175A (et
Inventor
Howard Carter Barry
Muse Partin Jane
Gregory Varlashkin Peter
Augustus Winnike Richard
Bayne Grubb William
Alan Conway Gregory
George Lake Philip
Michael Skinner David
James Whatrup David
Original Assignee
The Wellcome Foundation Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10768347&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE03528(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The Wellcome Foundation Limited filed Critical The Wellcome Foundation Limited
Publication of EE9700175A publication Critical patent/EE9700175A/et
Publication of EE03528B1 publication Critical patent/EE03528B1/et

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EE9700175A 1995-01-20 1996-01-19 Valatsükloviirvesinikkloriid, selle valmistamismeetod ja kasutamine EE03528B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9501178.9A GB9501178D0 (en) 1995-01-20 1995-01-20 Guanine derivative
PCT/GB1996/000117 WO1996022291A1 (en) 1995-01-20 1996-01-19 Guanine derivative

Publications (2)

Publication Number Publication Date
EE9700175A EE9700175A (et) 1998-02-16
EE03528B1 true EE03528B1 (et) 2001-10-15

Family

ID=10768347

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9700175A EE03528B1 (et) 1995-01-20 1996-01-19 Valatsükloviirvesinikkloriid, selle valmistamismeetod ja kasutamine

Country Status (40)

Country Link
US (1) US6107302A (et)
EP (1) EP0804436B1 (et)
JP (1) JP3176633B2 (et)
KR (1) KR100376074B1 (et)
CN (1) CN1049893C (et)
AP (1) AP662A (et)
AR (1) AR002270A1 (et)
AT (1) ATE302777T1 (et)
AU (1) AU702794B2 (et)
BG (1) BG63393B1 (et)
BR (1) BR9606768A (et)
CA (1) CA2210799C (et)
CY (1) CY2531B1 (et)
CZ (1) CZ297065B6 (et)
DE (1) DE69635106T2 (et)
DK (1) DK0804436T3 (et)
EA (1) EA000364B1 (et)
EE (1) EE03528B1 (et)
ES (1) ES2248806T3 (et)
FI (1) FI973063L (et)
GB (1) GB9501178D0 (et)
GE (1) GEP20001940B (et)
HR (1) HRP960024B1 (et)
HU (1) HU222993B1 (et)
IL (1) IL116831A (et)
IN (1) IN182468B (et)
IS (1) IS2268B (et)
NO (1) NO315558B1 (et)
NZ (1) NZ298851A (et)
OA (1) OA10499A (et)
PL (1) PL182175B1 (et)
RO (1) RO118693B1 (et)
RS (1) RS49518B (et)
SI (1) SI0804436T1 (et)
SK (1) SK285329B6 (et)
TR (1) TR199700656T1 (et)
UA (1) UA46001C2 (et)
UY (1) UY25779A1 (et)
WO (1) WO1996022291A1 (et)
ZA (1) ZA96449B (et)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501178D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Guanine derivative
AU722304B2 (en) * 1996-01-19 2000-07-27 Glaxo Group Limited Use of valaciclovir for the manufacture of a medicament for the treatment of genital herpes by a single daily application
IT1283447B1 (it) * 1996-07-18 1998-04-21 Ind Chimica Srl Processo di preparazione del valaciclovir e relativi intermedi
AU5495898A (en) * 1997-01-17 1998-08-07 Ajinomoto Co., Inc. Novel z-valacyclovir crystals
GB0010446D0 (en) * 2000-04-28 2000-06-14 Glaxo Wellcome Kk Pharmaceutical formulation
EE05735B1 (et) * 2001-02-24 2015-01-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ksantiini derivaadid, nende valmistamine ja kasutamine ravimina
CA2457835A1 (en) * 2001-09-07 2003-03-20 Teva Pharmaceutical Industries Ltd. Crystalline forms of valacyclovir hydrochloride
US20040197396A1 (en) * 2001-11-05 2004-10-07 Fain Helen S Anhydrous crystal form of valaciclovir hydrochloride
CN1307177C (zh) * 2001-11-14 2007-03-28 特瓦制药工业有限公司 伐昔洛韦的合成与纯化
AU2003240213A1 (en) * 2002-06-24 2004-01-06 Ranbaxy Laboratories Limited Process for the preparation of robust formulations of valacyclovir hydrochloride tablets
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US20050043329A1 (en) * 2002-09-06 2005-02-24 Shlomit Wizel Crystalline forms of valacyclovir hydrochloride
US20050059684A1 (en) * 2002-10-16 2005-03-17 Ben-Zion Dolitzky Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
WO2004035583A1 (en) * 2002-10-16 2004-04-29 Teva Pharmaceutical Industries Ltd. Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
EP1575953A1 (en) * 2002-12-09 2005-09-21 Texcontor Etablissement Anhydrous crystalline form of valacyclovir hydrochloride
AU2003232719A1 (en) * 2003-05-30 2005-01-21 Eos Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ticaret A.S. Novel crystalline forms of valacyclovir hydrochloride
WO2005000850A2 (en) * 2003-06-02 2005-01-06 Teva Pharmaceutical Industries, Ltd. Novel crystalline forms of valacyclovir hydrochloride
US20050192296A1 (en) * 2004-01-21 2005-09-01 Zvi Harel Process for the preparation of valacyclovir hydrochloride
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
CA2572268A1 (en) * 2004-06-30 2006-02-02 Teva Pharmaceutical Industries Ltd. Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
US20060178512A1 (en) * 2005-02-04 2006-08-10 Cheruthur Govindan Method for preparing amino acid esters of nucleoside analogues
WO2006127217A2 (en) * 2005-05-25 2006-11-30 Eli Lilly And Company Cyclopropanecarboxylate esters of acyclovir
EP1746098A1 (en) * 2005-07-21 2007-01-24 SOLMAG S.p.A. Valacyclovir polymorphs and a process for the preparation thereof
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US20070112193A1 (en) * 2005-11-14 2007-05-17 Khunt Mayur D Valacyclovir process
PE20080251A1 (es) * 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
MX2008014024A (es) 2006-05-04 2008-11-14 Boehringer Ingelheim Int Formas poliformas.
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
CN1903854B (zh) * 2006-08-09 2012-05-23 丽珠医药集团股份有限公司 一种合成盐酸伐昔洛韦的方法
US20080167325A1 (en) * 2006-12-27 2008-07-10 Bs Praveen Kumar Valacyclovir compositions
US20080281099A1 (en) * 2007-05-07 2008-11-13 Mayur Devjibhai Khunt Process for purifying valacyclovir hydrochloride and intermediates thereof
GB0710277D0 (en) * 2007-05-30 2007-07-11 Univ Birmingham Use of antivirals in the treatment of medical disorders
EP3542801A1 (en) * 2007-08-17 2019-09-25 Boehringer Ingelheim International GmbH Purin derivatives for use in the treatment of fap-related diseases
JPWO2009031576A1 (ja) * 2007-09-03 2010-12-16 味の素株式会社 バラシクロビル塩酸塩結晶の製造方法
US20090076039A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched valacyclovir
PE20091730A1 (es) * 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR101657960B1 (ko) * 2008-08-15 2016-09-20 베링거 인겔하임 인터내셔날 게엠베하 Ｆａｂ-관련 질환의 치료에 사용하기 위한 푸린 유도체
JP2012502081A (ja) 2008-09-10 2012-01-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糖尿病及び関連症状の治療のための組み合わせ治療
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
CN102256976A (zh) 2008-12-23 2011-11-23 贝林格尔.英格海姆国际有限公司 有机化合物的盐形式
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
CN107115530A (zh) 2009-11-27 2017-09-01 勃林格殷格翰国际有限公司 基因型糖尿病患者利用dpp‑iv抑制剂例如利拉利汀的治疗
CA2797310C (en) 2010-05-05 2020-03-31 Boehringer Ingelheim International Gmbh Glp-1 receptor agonist and dpp-4 inhibitor combination therapy
WO2011158252A1 (en) 2010-06-15 2011-12-22 Matrix Laboratories Ltd Process for the preparation of valacyclovir hydrochloride polymorphic form ii
EP3124041A1 (en) 2010-06-24 2017-02-01 Boehringer Ingelheim International GmbH Diabetes therapy
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
CN102584825B (zh) * 2011-01-17 2014-04-02 四川科伦药物研究有限公司 一种合成盐酸伐昔洛韦的方法
HUE061596T2 (hu) 2011-07-15 2023-07-28 Boehringer Ingelheim Int Szubsztituált dimer kinazolin származék, annak elõállítása és alkalmazása az I. és II. típusú cukorbetegség kezelésére szolgáló gyógyszerkészítményekben
WO2013076688A1 (en) * 2011-11-25 2013-05-30 Piramal Enterprises Limited A process for the preparation of valacyclovir hydrochloride
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP3685839A1 (en) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin for use in the treatment of albuminuria and kidney related diseases
EP4151218A1 (en) 2012-05-14 2023-03-22 Boehringer Ingelheim International GmbH Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
WO2015128453A1 (en) 2014-02-28 2015-09-03 Boehringer Ingelheim International Gmbh Medical use of a dpp-4 inhibitor
US10155000B2 (en) 2016-06-10 2018-12-18 Boehringer Ingelheim International Gmbh Medical use of pharmaceutical combination or composition
CN110437231B (zh) * 2019-09-04 2022-04-29 上药康丽（常州）药业有限公司 一种盐酸伐昔洛韦无水晶型ⅰ的制备方法
WO2021209563A1 (en) 2020-04-16 2021-10-21 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP160A (en) * 1987-08-15 1991-11-18 The Wellcome Foundation Ltd Therapeutic acyclic nucleosides.
US5831075A (en) * 1993-06-10 1998-11-03 Rolabo Sl Amino acid ester of nucleoside analogues
GB9501178D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Guanine derivative

Also Published As

Publication number Publication date
SK285329B6 (sk) 2006-11-03
EA199700124A1 (ru) 1997-12-30
JPH11503718A (ja) 1999-03-30
ES2248806T3 (es) 2006-03-16
MX9705462A (es) 1997-10-31
IL116831A0 (en) 1996-05-14
NO315558B1 (no) 2003-09-22
IL116831A (en) 1998-10-30
EP0804436B1 (en) 2005-08-24
AP662A (en) 1998-08-19
CA2210799A1 (en) 1996-07-25
RS49518B (sr) 2006-10-27
JP3176633B2 (ja) 2001-06-18
YU3396A (sh) 1998-12-23
FI973063A7 (fi) 1997-09-18
AU4453996A (en) 1996-08-07
RO118693B1 (ro) 2003-09-30
DE69635106D1 (de) 2005-09-29
KR100376074B1 (ko) 2003-06-02
AP9701058A0 (en) 1997-10-31
DE69635106T2 (de) 2006-06-08
NO973326D0 (no) 1997-07-18
GEP20001940B (en) 2000-02-05
EA000364B1 (ru) 1999-06-24
IN182468B (et) 1999-04-17
US6107302A (en) 2000-08-22
EE9700175A (et) 1998-02-16
AU702794B2 (en) 1999-03-04
NZ298851A (en) 1999-01-28
HUP9801836A3 (en) 1999-06-28
SI0804436T1 (sl) 2006-02-28
BR9606768A (pt) 1997-12-30
CA2210799C (en) 2008-06-10
OA10499A (en) 2002-04-10
AR002270A1 (es) 1998-03-11
SK96597A3 (en) 1998-02-04
UA46001C2 (uk) 2002-05-15
NO973326L (no) 1997-09-16
GB9501178D0 (en) 1995-03-08
IS4527A (is) 1997-07-15
ATE302777T1 (de) 2005-09-15
KR19980701525A (ko) 1998-05-15
HU222993B1 (hu) 2004-01-28
PL182175B1 (pl) 2001-11-30
DK0804436T3 (da) 2005-12-27
BG101833A (bg) 1998-04-30
UY25779A1 (es) 2000-08-21
BG63393B1 (bg) 2001-12-29
CN1049893C (zh) 2000-03-01
FI973063L (fi) 1997-09-18
ZA96449B (en) 1996-08-07
IS2268B (is) 2007-07-15
TR199700656T1 (xx) 1998-03-21
CN1179159A (zh) 1998-04-15
EP0804436A1 (en) 1997-11-05
HRP960024B1 (en) 2005-08-31
CY2531B1 (en) 2006-04-12
CZ229497A3 (en) 1997-12-17
CZ297065B6 (cs) 2006-08-16
PL321326A1 (en) 1997-12-08
FI973063A0 (fi) 1997-07-18
WO1996022291A1 (en) 1996-07-25
HRP960024A2 (en) 1997-10-31
HUP9801836A2 (hu) 1999-05-28

Similar Documents

Publication Publication Date Title
EE03528B1 (et) Valatsükloviirvesinikkloriid, selle valmistamismeetod ja kasutamine
EE03338B1 (et) Tromboosivastane ravim, selle valmistamise protsess ja kasutamine
CY2013003I2 (el) Φωσφονοκεφεμικα παραγωγα, διαδικασια για την παρασκευη τους, και χρηση αυτων
EE03482B1 (et) Kinasoliiniderivaadid, nende valmistamismeetod ja kasutamine
DE69612854D1 (de) Spannfutter
DE59510926D1 (de) Bohrfutter
DE19581725T1 (de) Spannfutter
EE03568B1 (et) Bensimidasooli derivaadid, nende valmistamismeetod ja kasutamine
FI962917A7 (fi) Mikrokapselit, menetelmä niiden valmistamiseksi, ja niiden käyttö
DE69528980D1 (de) Bohrfutter
FI980023L (fi) Sienilääke, siihen soveltuva yhdiste, menetelmä niiden valmistamiseksi ja menetelmä niiden käyttämiseksi
DE69514175D1 (de) Spannfutter
DE69605743D1 (de) Druckverfahren
DE69520558D1 (de) Halogenierungsverfahren
BR9501980A (pt) Copolimeros,processo para sua preparação
DK1044183T3 (da) Amineringsproces
NO974169D0 (no) Fremgangsmåte for tetra-azacykloalkan-fremstilling
DE69603161D1 (de) Druckverfahren
FI972264L (fi) Betaiinituote, menetelmä sen valmistamiseksi, ja sen käyttö
FI931232L (fi) Makeutusaine, menetelmä sen valmistamiseksi ja sen käyttö
DK0726265T3 (da) 10-Aminoaliphatyl-dibenz[b,f]oxepiner med antineurodegenerativ virkning
FI954946A7 (fi) Kinoksaliinit, menetelmä niiden valmistamiseksi ja niiden käyttö
EE03387B1 (et) Kombineeritud ravimpreparaat, selle kasutamine ja meetod selle valmistamiseks
DK0727416T3 (da) Substituerede benzensulfonylurinstoffer og -thiourinstoffer, og fremgangsmåde til deres fremstilling, deres anvendelse som
DE69507032D1 (de) Chlorhydrin-verfahren

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20021231

KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20091231

KB4A Valid patent at the end of a year

Effective date: 20101231

MM4A Lapsed by not paying the annual fees

Effective date: 20110119